

MICHAEL L. CHER, M.D.

Office: Department of Urology
Wayne State University School of Medicine
4201 St. Antoine, UHC-7C
Detroit, MI 48201

EDUCATION AND EXPERIENCE

9/78 - 6/82 Stanford University, Bachelor of Science in Chemistry with Distinction, Palo Alto, California

8/82 - 5/86 Washington University School of Medicine, Doctor of Medicine, St. Louis, Missouri

TRAINING

7/86 - 6/88 Resident in General Surgery, the University of Texas Southwestern Medical School, Dallas, Texas

7/88 - 6/92 Resident in Urology, The University of Texas Southwestern Medical School, Dallas, Texas

7/89 - 6/90 National Kidney Foundation Fellow, Urology Laboratory, The University of Texas Southwestern Medical School, Dallas, Texas

7/92 - 7/95 Clinical and Research Fellow in Urologic Oncology and Molecular Cytogenetics, The Department of Urology and The Department of Laboratory Medicine (Division of Molecular Cytometry), University of California School of Medicine, San Francisco, California

7/93 - 7/95 Research Scholar, American Foundation for Urologic Disease, The Department of Urology and The Department of Laboratory Medicine (Division of Molecular Cytometry), University of California School of Medicine, San Francisco, California

FACULTY APPOINTMENTS

7/92 – 7/95 Instructor, Department of Urology, University of California, San Francisco School of Medicine

8/95-7/01 Assistant Professor, Departments of Urology and Pathology and the Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan

7/01-12/05	Associate Professor, Departments of Urology and Pathology and the Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
1/02-12/05	Donald J. Jaffar, MD, Endowed Research Chair, Department of Urology, Wayne State University School of Medicine
1/06 – 8/06	Interim Chair, Department of Urology, Wayne State University School of Medicine
1/06 – present	Professor, Departments of Urology, Pathology, and Oncology, Wayne State University School of Medicine
1/06 – present	Dorothy and Donald Jaffar Endowed Professor, Department of Urology, Wayne State University School of Medicine
9/06 – present	Chair, Department of Urology, Wayne State University School of Medicine and Wayne State University Physician Group Department of Urology

HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS

7/92 - 7/95	Staff appointment, the hospitals of the University of California, San Francisco School of Medicine
8/95-present	Staff appointment, The hospitals of the Detroit Medical Center
8/95-2/06 5/15-present	Staff Surgeon, Urology Section, The Detroit VA Medical Center
8/95-9/97	Director, Quantitative Image Processing Core Facility, Karmanos Cancer Institute of Wayne State University
1/04-present	Director of Urologic Oncology, Wayne State University School of Medicine
1/04-present	Member, Scientific Leadership Council, Karmanos Cancer Center
9/05-present	Chief of Urology, Barbara Ann Karmanos Cancer Center
1/06 – 12/06	Urology Specialist-in-Chief, Detroit Medical Center
1/06 – present	Medical Staff, Oakwood Hospital and Medical Center
6/06 – present	Member, Board of Directors, Wayne State University Physician Group
11/07 – present	Member, Clinical Leadership Council, The Barbara Ann Karmanos Cancer Center
6/10 – present	Member, Medical Staff Leadership Council, The Barbara Ann Karmanos Cancer Center

MAJOR PROFESSIONAL SOCIETIES

American Urological Association
Society for Basic Urologic Research
American Association for Cancer Research
Southwest Oncology Group
Society of Urologic Oncology
Society of University Urologists
Urological Research Society (Elected Member 2015)

LICENSURE AND BOARD CERTIFICATION

Licensure in the State of Michigan
Licensure in the State of California
Licensure in the State of Texas
Board Certified by the American Board of Urology – 1997 # 11423
Recertification by the American Board of Urology – 2006

HONORS AND AWARDS

7/80 - 7/81 Rotary Foundation Award for International Understanding, for study at the Hebrew University

6/82 Phi Lambda Upsilon, Honorary Chemistry Society

6/82 Phi Beta Kappa of California

7/89 National Kidney Foundation/American Foundation for Urologic Disease Resident Fellow

4/90 First Prize, Resident's Essay Contest, Texas Urological Society

10/90 First Prize, Resident's Essay Contest, South Central Section of the American Urological Association

2/92 Resident/Fellow Award of Excellence, Grand Teton Urologic Conference

7/93 Research Fellow, National Kidney Foundation

7/93 Research Scholar, American Foundation for Urologic Disease

5/94 Circon/ACMI Essay Competition, Second Place, Western Section of the American Urological Association

4/95 Best Poster: Prostate Cancer Molecular Markers, American Urological Association Annual Meeting

11/95 Association for the Cure of Cancer of the Prostate (CaPCURE) Research Award

- 3/98 Research Mentor to Mireille Kattar, Pathology Fellow, who received of Stowell-Orbison Award of the United States and Canadian Academy of Pathology (national award) for work done in my laboratory
- 3/98 1997 Karmanos Cancer Institute Performance Recognition Award
- 4/98 Travel grant award from the National Academy of Sciences/National Research Council, U.S. National Committee for the International Union Against Cancer to attend the 17th International Congress of the Union Internationale Contre Cancer, Rio de Janeiro, Brazil
- 10/99 Pierre Fabre Medicament ARTP Prize, The 3rd World Congress on Urological Research, Paris, France. Awarded by the "Association pour la Recherche sur les Tumeurs de la Prostate" to the best prostate cancer research presentation
- 1/00 Association for the Cure of Cancer of the Prostate (CaPCURE) Research Award
- 4/00 2000 Society for Basic Urologic Research/Merck Young Investigator Award
- 1/01 2000 President's Achievement Award, The Barbara Ann Karmanos Cancer Institute, for Clinical/Translational Research
- 1/02 – 12/03 Career Development Chair, Wayne State University
- 5/06 Society of Urologic Oncology CapCURE Award for one of three best prostate cancer abstracts at AUA Meeting, Atlanta, GA.
- 2008, 2009, 2010, 2011, 2012, 2013 Hour Magazine of Detroit Urology "Top Doc"
- 10/13 Best Poster, Prostate Cancer Session, North Central Section of the American Urological Association, Naples, FL.
- 1/15 Induction into Gold Humanism Honor Society, a program to recognize integrity, excellence, compassion, altruism, respect and empathy in medicine.

SERVICE

Patient Care:

- 8/95 – present Outpatient and inpatient urologic care to patients through the hospitals of The Detroit Medical Center and The Barbara Ann Karmanos Cancer Institute, The John D. Dingell Veterans Affairs Medical Center, Oakwood Hospital and Medical Center.

Professional Consultation:

- 2001 – present Legal consultation/defense expert witness on various medical malpractice cases
- 2001 – present Consultant/Advisory Board to Merck, Amgen, Bayer, Dendreon, and

several smaller pharmaceutical companies regarding prostate cancer clinical trials issues

2010 – present Speaker's Bureau, Amgen, Astellas/Medivation

Journal/Editorial Activity:

Book Editor:

2002 Prostate Cancer: New Horizons in Research and Treatment. Edited by **ML Cher**, A Raz and KV Honn. Series: Developments in Oncology, Vol. 81, 2002, Kluwer Academic Publishers, Boston, MA.

Guest Editor for Journal:

9/01-9/02 Invited Guest Editor for three issues of Cancer and Metastasis Reviews devoted to Prostate Cancer clinical and basic research.

Journal Editorial Board:

3/02 – present Cancer and Metastasis Reviews

9/08 – present The Open Prostate Cancer Journal

3/12—present Frontiers in Genitourinary Oncology

Ongoing Ad hoc Journal Reviewer Activity:

Urology; Journal of Urology; Genes, Chromosomes & Cancer; European Urology; International Journal of Cancer; Cytometry; British Journal of Cancer; Cancer Research; Clinical Cancer Research; American Journal of Pathology; Journal of the National Cancer Institute, Cancer Letters, Journal of Bone and Mineral Metabolism Research, Clinical and Experimental Metastasis, Prostate, Neoplasia, Oncogene and others.

Grant Review Study Section Activity:

3/99 Member, Special Review Committee, for Review of proposals to the NCI in response to PAR-98-092, "Shared Resources for Scientists Outside NCI Cancer Centers"

3/00 Member, Special Review Committee, for Review of proposals to the NCI in response to PAR-98-092, "Shared Resources for Scientists Outside NCI Cancer Centers"

7/00 Member, Cell Biology Study Section (CBY-2), Fiscal Year 2000 United States Department of Defense Prostate Cancer Research Program

2/01 Member, Special NCI/CSR Study Section for Program Project Site Visit, Penn State University

1/02	NCI/CSR Study Section for evaluation of Prostate Cancer SPOREs
2/03-7/03	NCI/CSR Pathology B Study Section, Ad Hoc Member
9/04	NCI/CSR Prostate Cancer Program Project Cluster Review Committee, Ad Hoc Member
6/05	Congressionally Directed Medical Research Programs (CDMRP) Prostate Cancer Research Program (PCRP) programmatic review (second tier review for programmatic relevance), Ad Hoc Member
10/03 – present	Charter Member, NCI/CSR Tumor Microenvironment (TME) Study Section
6/05	Department of Defense Prostate Cancer Research Program, Integration Panel (Second Level Programmatic Review, Ad Hoc Member
10/05	NIH/CSR Reviewer for Quick-Trials in Image-Guided Interventions, PAR-05-114.
6/06	NIH/CSR Reviewer for Quick-Trials in Image-Guided Interventions, PAR-05-114.
6/06	Member, Pathobiology Study Section (PBY-2), Fiscal Year 2006 United States Department of Defense Prostate Cancer Research Program.
9/06	NIH/NCI Reviewer, University of California San Diego NCI-designated Comprehensive Cancer Center.
10/08	American Urological Association Foundation Research Scholar Review Committee.
10/11	Terry Fox Cancer Research Institute, Canada, Prostate Cancer Research Program.
10/12	Chair, Review Panel, Congressionally Directed Medical Research Programs (CDMRP) Prostate Cancer Research Program, Clinical Exploration Award
7/13	Member, Review Panel, National Clinical Trials Network Lead Academic Participating Site Review for NIH.
2/14/14	Member, Review Panel, NIH Specialized Programs of Research Excellence (SPOREs) for Prostate, Kidney, Lymphoma Cancers
6/14/14	Member, Review Panel, NIH Specialized Programs of Research Excellence (SPOREs) for Prostate Cancer
11/4/14	NCI Omnibus Review (R03 and R21)
11/15	Chair, DOD Impact-1 Study Section

Miscellaneous Other Grants Reviewed:

1995-present	Grants Review Committee Member, Wayne State University Prostate Cancer Initiative.
1995-present	Grants Review Committee Member, Virtual Discovery Program, Karmanos Cancer Institute, Wayne State University.
12/96	External Reviewer for Natural Sciences and Engineering Research Council of Canada.
8/97	Cancer Society of New Zealand
3/01	The Health Research Board of Ireland
3/06	Italian Cancer Research Association

Program/Organizing Committee for National Meetings:

4/02	Third North American Symposium on Skeletal Complications of Malignancy sponsored by NCI and Paget's Foundation, Bethesda, MD
2003	American Association for Cancer Research (AACR) Annual Meeting: Invasion and Metastasis Section
2012	Friends of Israel Urological Symposium, Tel Aviv, Israel, July, 2012.

National/Regional Committees:

8/06-6/10	American Urological Association Education Council Member
9/11 – present	Board Member, Cryotherapy On-Line Database, for management of prostate cancer with cryotherapy
10/12 – present	Member, Executive Committee, Michigan Urologic Surgery Improvement Collaborative

Committees/University Service:

12/98	Established surgical procedure database (for the Urology residents) for the WSU Department of Urology in order to help maintain our residency program accreditation
1998	Developed web site for WSU Department of Urology
8/96 - 8/98	Faculty Recruitment Committee - WSU Center for Molecular Medicine and Genetics
1/97-1/99	Detroit Veteran's Hospital Ambulatory Care Committee Co-chairperson
10/99	Internal Review Committee for the Departmental Review for the WSU Department of Urology

7/98 – 12/99	Ph.D. Committee for WSU graduate student Fatimah Nahhas
10/00	Organizer of the “Tenth Annual Pierce Memorial Lectureship” of the WSU Department of Urology, involving 14 invited speakers, 8 local speakers and CME credit, Troy, Michigan
5/00 – 5/02	Ph.D. Committee for WSU graduate student Hector Biliran
5/00 – 5/03	Ph.D. Committee for WSU graduate student Megan Schober
11/02 – 3/03	Member, WSU Urology Department Chair Search Committee
6/00 – 6/04	Protocol Review Committee of the Clinical Trials Office of The Barbara Ann Karmanos Cancer Institute
9/03 – 7/04	Member, Search Committee for The Barbara Ann Karmanos Cancer Institute Associate Center Director, Basic Science/Deputy Director
3/00 – present	Member, Scientific Advisory Committee for the WSU School of Medicine
2/03 - present	Karmanos Cancer Institute Representative and Speaker for various fundraising events
1/04 – 6/12	Faculty Member, WSU School of Medicine Cancer Biology Graduate Program
4/04 – 7/07	Ph.D. Committee for WSU graduate student Alaina Powell
8/04 – 6/05	Review Committee for WSU Department of Anesthesiology
8/04 – 3/09	Mentor, WSU Ph.D. Graduate Student Aaron Sabbota. Received Ph.D. in 3/09 for work in my laboratory
3/09 – 10/09	Member, Search Committee for The Barbara Ann Karmanos Cancer President and Chief Executive Officer
6/10-present	Member, Internal Advisory Committee for Karmanos Cancer Institute Systems and Computational Biology Core
7/11 – present	Member, Karmanos Cancer Institute Faculty Development and Mentoring Program Council
7/11 – present	Member, Karmanos Cancer Center Hospital Performance Improvement Committee
9/11 – present	Faculty advisor, Music in Medicine Program, WSU School of Medicine student group
1/12 – present	Ph.D. Committee for WSU Graduate Student Katelyn Powell
7/13– present	Member, Governance and Nominating Committee, Wayne State

University Physician Group Board of Directors

Community:

- 9-10/98 Physician Examiner at Prostate Cancer Screening Program, Detroit area churches
- 1/99 Speaker for American Cancer Society Northern Michigan Branch Fund Raiser, Traverse City, Michigan
- 4/99-8/99 Medical Leadership Speaker at multiple "Relay for Life" fund raising events in Southeastern Michigan for the Michigan branch of the American Cancer Society
- 2000 Member, Jewish Advisory Committee to Hospice of Michigan
- 10/00 Invited Speaker, Crittenton Hospital Prostate Cancer Support Group, "Prostate Cancer Bone Metastasis," Rochester, Michigan
- 1/05 Invited Speaker, Brave Support Group, The Barbara Ann Karmanos Cancer Institute, "Prostate Cryotherapy," Detroit, Michigan
- 3/05 Invited Speaker, Beaumont Hospital Prostate Cancer Support Group, "Prostate Cancer Bone Metastasis," Royal Oak, Michigan
- 3/05 Invited Speaker, Crittenton Hospital Prostate Cancer Support Group, "Prostate Cancer Bone Metastasis," Rochester, Michigan
- 3/05 Invited Speaker, Congregation Beth Shalom, "Men's Health," Oak Park, Michigan
- 3/04 – present Participant in Project Chesed of the Jewish Family Service of Detroit: provision of pro-bono medical care for Jewish patients without any medical insurance coverage
- 7/04 – present WSU Medical Student Mentoring program
- 4/09 Recipient of National Shin Award (Michael Cher and Lisa Yufit) from Jewish Theological Seminary in New York for support of Jewish Education
- 4/09 – present Faculty Advisor, Board Member, incorporating agent, and principal clarinetist, Detroit Medical Orchestra, Detroit, MI.
- 7/13—present Member, Board of Directors, and clarinetist, Spectrum Orchestra, Birmingham, MI. Guest orchestra conductor, May, 2013, concert.

TEACHING

Wayne State University faculty since 1995**Courses:**

7/96 – 7/98	Monthly lectures to third year medical students on surgery rotation – “Benign Prostatic Hyperplasia and Prostate Cancer.”
7/96 – 7/98	Organized weekly textbook review course (“Campbell’s Club”) for Wayne State University urology residents.
4/98	Molecular Biology and Genetics (MBG 103) Lecturer to graduate students
4/00	Invited speaker to graduate-level Cancer Biology Class at The University of Chicago
4/01	Invited speaker to graduate-level Cancer Biology Class at The University of Chicago
1998 – present	Gross Anatomy instructor (ad hoc): Surgical approaches to the retroperitoneum
7/99 – present	Organized and invited speakers for weekly Urology Grand rounds
7/99 – present	Organized Urology Department Monthly Journal Club
2006 – present	Annual lectures to medical students on GU physical examination

Research Trainees:

7/97 – 6/98	Mireille Kattar, M.D., pathology resident/fellow
7/97 – 6/01	Jeffrey Nemeth, Ph.D., post-doctoral research associate
6/99 – 9/99	Mentor to Mr. Jason Roberts, Summer Research Trainee under Grant for Medical Students (\$1920)
8/01	Mentor to Mr. Rick Bennett, Summer Medical Student Research Trainee
7/01 – 6/02	Lusia Cristina Filetti, M.D., international post-doctoral fellow
8/95 – 6/03	Urology Residents while on Research Rotations: John Harb, Patrick Hurley, David Heiser, Jyoti Upadhyay, Bijan Shekarriz, Rafid Yousif, Ashok Reddy, Michael Herzog, Vivek Narain, Fernando Bianco, Michael Zachareas, Yao-Jen Chang
1/02 – 6/04	Xiyun Deng, Ph.D., post-doctoral research associate
7/02 – 10/04	Jose Carlos Trindade, M.D., international post-doctoral research associate
8/01 – present	Sreenivasa Chinni, Ph.D., Assistant Professor (Research); now Associate

Professor (tenure track)

- 9/01 – 6/08 Zhong Dong, Ph.D., post-doctoral fellow
- 7/02 – present R. Daniel Bonfil, Ph.D., Associate Professor (Research)
- 6/04 – 6/08 Sanaa Nabha, Ph.D., post-doctoral fellow
- 1/05 – 3/06 Hamilto Yamamoto, M.D., international post-doctoral fellow
- 3/05 – 3/06 Christoph Weisner, M.D., international post-doctoral fellow
- 12/05 – 3/09 PhD advisor to Aaron Sabotta, graduate student in Cancer Biology

Clinical Trainees:

- 10/98 – 11/99: Designated Mentor to Urology Resident Ashok Reddy for review of basic urologic knowledge
- Ongoing Eight urology residents each year in the operating room, on the hospital wards, and in the urology clinics throughout the year

Conferences:

Faculty participant in weekly urologic oncology conferences and grand rounds conferences and monthly journal clubs

Other:

- 11/96 Basic Medical Science Degree Essay Evaluation Committee for Bharat Talati, candidate for Masters of Science, Wayne State University
- 1997 Fourth Year Medical Student Advisor, Jason Halleran
- 1998 Course Director, Graduate Student Independent Study, Chris Pierson
- 1999 Mentor, Summer Research Grant for Medical Students (\$1920), Jason Roberts
- 2004 – 2009 Mentor, Ph.D. Supervisor, WSU Ph.D. Graduate Student Aaron Sabbota
- 2002—present Graduate Student committees for several cancer biology graduate students including Megan Schoeber, Alaina Powell, Seaho Kim.

GRANT SUPPORT: MICHAEL L. CHER, M.D., PRINCIPAL INVESTIGATOR:

- 8/95-7/97 National Cancer Institute Prostate Cancer Development Grant and Wayne State

- University Prostate Initiative, Principal Investigator of Pilot Project: Genomic alterations and cellular proliferation in prostate cancer in African Americans (\$80,000)
- 11/95 - 10/96 Association for the Cure of Cancer of the Prostate (CaPCURE): Genomic alterations and cellular proliferation in prostate cancer in African Americans (\$100,000)
- 3/96-2/98 National Cancer Institute Prostate Cancer Development Grant and Wayne State University Prostate Initiative, Principal Investigator of Pilot Project: Genetic analysis of prostate cancer bone marrow micrometastases (\$80,000)
- 1/97 - 12/99 American Cancer Society: Genetic Analysis of Prostate Cancer Micrometastases (\$442,000)
- 10/97 - 10/99 National Cancer Institute Prostate Cancer Development Grant and Wayne State University Prostate Initiative, Principal Investigator of Pilot Project: SCID-human bone marrow model of human prostate cancer metastasis (\$80,000)
- 5/99 - 4/00 The Barbara Ann Karmanos Cancer Institute Virtual Discovery Grant Program: Development of Confocal Microscopic Techniques to Study the Biology of MMP-directed Bone Degradation by Prostate Cancer Cells in a SCID-human Model and Organ Culture Model (\$20,000)
- 1/00-12/00 United States Department of Defense Prostate Cancer Research Program: A Novel Approach to Manipulate the Human bone Microenvironment in Prostate Cancer: Prevention of Bone Matrix Degradation by Inhibition of Matrix Metalloproteinase (\$175,000)
- 1/00-12/00 Association for the Cure of Cancer of the Prostate (CaPCure): Genetically Modified Bone Stroma in the SCID-Human Model: A Novel Experimental Approach for Therapy of Prostate Cancer Bone Metastasis (\$75,000)
- 7/00-6/05 National Cancer Institute R01 CA88028: Prostate Cancer, Bone Metastasis, and Metalloproteinases (\$1,350,000)
- 8/00-7/12 Southwestern Oncology Group: SELECT Prostate Cancer Prevention Study. Michael L. Cher, M.D., Principal Investigator for Wayne State University and The Barbara Ann Karmanos Cancer Institute. (Funding on a per-patient basis)
- 1/02-1/05 United States Department of Defense Prostate Cancer Research Program: Creation of a Bone Environment Hostile to Prostate Cancer (\$550,000)
- 10/02-9/04 Activities to Promote Research Collaborations: Supplement to R01 CA 88028 (Cher) and CA84176 (Sheng): Interaction of Urokinase and MMP Pathways in Prostate Cancer Bone Metastasis M. Cher and S. Sheng, Co-PI's (\$80,000)
- 3/03-2/06 DOD Consortium Grant: A Synergy Consortium Targeting the Lethal Phenotype of Prostate Cancer, Jonathan Simons, PI (Emory University). M. Cher: WSU PI of 2 Projects on Prostate Cancer Bone Metastasis (WSU amount: \$484,000)
- 6/02 – present Southwest Oncology Group Urologic Cancer Outreach Program, M. Cher, PI, for

WSU and The Barbara Ann Karmanos Cancer Institute

- 9/03 – 9/08 National Institute Of Diabetes And Digestive And Kidney Diseases
R01DK067678-01: Proteases in Prostate Cancer Bone Metastasis (\$2,324,266)
- 7/09 – 6/12 NCI 1R01CA137280-01A1 (Cher) The MT1-MMP/RANKL/RANK Axis in Prostate
Cancer Bone Metastasis (\$909,524).
- 6/11 – 6/14 #KCI-2011-2 (Kim, Cher, Bonfil co-Pis) National Oncogenomic and Molecular
Imaging Center, “Genomic profiling of circulating tumor cells and bone
metastasis in prostate cancer.” (\$300,000).

GRANT SUPPORT AS CO-INVESTIGATOR:

- 11/93 - 10/94 Association for the Cure of Cancer of the Prostate (CaPCure) Research Award,
Co-Investigator: Identification of a tumor suppressor gene for prostate
adenocarcinoma on chromosome 16q. Ron Jensen, P.I. (\$150,000)
- 3/97 - 9/98 Karmanos Cancer Institute **Co-Investigator**: Mechanisms of Chromosomal
Instability in Human Prostate Cancer. Jeff Virgin, P.I. (\$72,999)
- 4/97 - 12/99 National Cancer Institute Cancer Center Support Grant to Karmanos Cancer
Institute, **Director**, Quantitative Fluorescence Image Processing core facility.
William Peters, P.I.
- 12/15/98 Association for the Cure of cancer of the Prostate (CaPCURE) Research Award,
Co-investigator: Arachidonate 12-Lipoxygenase Inhibitors for Anti-
Angiogenesis Therapy of Prostate Cancer. Ken Honn, P.I. (\$75,000)
- 4/99 - 3/01 National Cancer Institute Prostate Cancer Development Grant and Wayne State
University Prostate Initiative, Co-Investigator of Pilot Project: The Role of
Cathepsins B and K in Bone Degradation by Metastatic Prostate Cancer. Bonnie
Sloane, P.I. (\$80,000)
- 5/99 - 4/00 The Barbara Ann Karmanos Cancer Institute Virtual Discovery Grant Program:
Molecular Signature of Cancer Cells. Fazlul Sarkar, P.I. (\$20,000)
- 10/99-9/02 United States Army Prostate Cancer Research Program, **Co-Investigator**:
Cathepsins B and K: Role in Metastasis of Human Prostate Cancer to Human
Bone in an In Vivo SCID-human Mouse Model. Bonnie Sloane, P.I. (\$557,582)
- 9/01-8/31/02 National Cancer Institute R01 **Co-Investigator**: Molecular Mechanism of
Genistein in Prostate Cancer. Fazlul Sarkar, P.I. (\$966,485)
- 2/04 to 1/07 United States Army Prostate Cancer Research Program, **Co-Investigator**: PET
Imaging of Prostate Cancer with Fluoropyrimidines. Anthony Shields, P.I.
- 2/08-1/13 NCI CA127735 (Sheng) A role of novel serpin maspin in prostate cancer/bone
interaction.
- 1/10-12/13 PDGF D and Prostate Cancer Bone Metastasis. (Kim) RO1 NCI/NIH CA123362.

7/12-6/15 United States Army Prostate Cancer Research Program, **Consultant:** Wnt/beta-Catenin, Foxa2, and CXCR4 axis controls prostate cancer progression (Yu X, Vanderbilt U.)

PUBLICATIONS

ORIGINAL ARTICLES IN REFEREED JOURNALS

1. Waleh A, **Cher ML**, Loew GH, Mueller-Westerhoff UT: Electronic structure, geometry, and energetics of carbanion and carbocation of (1.1) ferrocenophane: An INDO study. *Theoretica Chimica Acta* 65:167-177, 1984.
2. **Cher ML**, Allen TD. Continence in the myelodysplastic patient following enterocystoplasty. *The Journal of urology*. 1993;149(5):1103-6. PubMed PMID: 8483222.
3. **Cher ML**, Milchgrub S, Sagalowsky AI. Transitional cell carcinoma of the ureteral stump 23 years after radical nephrectomy for adenocarcinoma. *The Journal of urology*. 1993;149(1):106-8. PubMed PMID: 8417186.
4. **Cher ML**, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. *Genes, chromosomes & cancer*. 1994;11(3):153-62. PubMed PMID: 7530484.
5. **Cher ML**, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. *The Prostate*. 1995;26(2):87-93. PubMed PMID: 7855002.
6. **Cher ML**, Ito T, Weidner N, Carroll PR, Jensen RH. Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). *The Journal of urology*. 1995;153(1):249-54. doi: 10.1097/00005392-199501000-00086. PubMed PMID: 7966782.
7. **Cher ML**, Shinohara K, Breslin S, Vapnek J, Carroll PR. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. *British journal of urology*. 1995;75(6):771-7. PubMed PMID: 7542137.
8. Wolf JS, Jr., **Cher M**, Dall'era M, Presti JC, Jr., Hricak H, Carroll PR. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. *The Journal of urology*. 1995;153(3 Pt 2):993-9. PubMed PMID: 7853590.
9. **Cher ML**, Abernathy BB, McConnell JD, Zimmern PE, Lin VK. Smooth-muscle myosin heavy-chain isoform expression in bladder-outlet obstruction. *World journal of urology*. 1996;14(5):295-300. PubMed PMID: 8912469.
10. **Cher ML**, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. *Cancer research*. 1996;56(13):3091-102. PubMed PMID: 8674067.

11. **Cher ML**, Stephenson RA, James BC, Carroll PR. Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer. *The Journal of urology*. 1996;155(5):1674-7. PubMed PMID: 8627851.
12. Yeatman TJ, **Cher ML**, Mao W, Wloch M, Tedesco T. Identification of genetic alterations associated with the process of human experimental colon cancer liver metastasis in the nude mouse. *Clinical & experimental metastasis*. 1996;14(3):246-52. PubMed PMID: 8674279.
13. Connolly JA, Presti JC, Jr., **Cher ML**, Chew K, Shinohara K, Carroll PR. Accelerated tumor proliferation rates in locally recurrent prostate cancer after radical prostatectomy. *The Journal of urology*. 1997;158(2):515-8. PubMed PMID: 9224336.
14. Godfrey TE, **Cher ML**, Chhabra V, Jensen RH. Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. *Cancer genetics and cytogenetics*. 1997;98(1):36-42. PubMed PMID: 9309116.
15. Moore DH, 2nd, Pallavicini M, **Cher ML**, Gray JW. A t-statistic for objective interpretation of comparative genomic hybridization (CGH) profiles. *Cytometry*. 1997;28(3):183-90. PubMed PMID: 9222102.
16. **Cher ML**, Bianco FJ, Jr., Lam JS, Davis LP, Grignon DJ, Sakr WA, Banerjee M, Pontes JE, Wood DP, Jr. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. *The Journal of urology*. 1998;160(4):1387-91. PubMed PMID: 9751361.
17. **Cher ML**, Lewis PE, Banerjee M, Hurley PM, Sakr W, Grignon DJ, Powell IJ. A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian Americans. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 1998;4(5):1273-8. PubMed PMID: 9607587.
18. Gheiler EL, Tefilli MV, Tiguert R, Grignon D, **Cher ML**, Sakr W, Pontes JE, Wood DP, Jr. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. *Urology*. 1998;51(5):789-95. PubMed PMID: 9610593.
19. Mueller P, Carroll P, Bowers E, Moore D, 2nd, **Cher M**, Presti J, Wessman M, Pallavicini MG. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. *Cancer*. 1998;83(3):538-46. PubMed PMID: 9690547.
20. Triest JA, Grignon DJ, **Cher ML**, Kocheril SV, Montecillo EJ, Talati B, Tekyi-Mensah S, Pontes JE, Hillman GG. Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 1998;4(8):2009-14. PubMed PMID: 9717832.
21. Wood DP, Jr., Beaman A, Banerjee M, Powell I, Pontes E, **Cher ML**. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 1998;4(9):2119-23. PubMed PMID: 9748128.
22. **Cher ML**, de Oliveira JG, Beaman AA, Nemeth JA, Hussain M, Wood DP, Jr. Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 1999;5(9):2421-5. PubMed PMID: 10499613.

23. Kattar MM, Grignon DJ, Eble JN, Hurley PM, Lewis PE, Sakr WE, **Cher ML**. Chromosomal analysis of renal angiomyolipoma by comparative genomic hybridization: evidence for clonal origin. *Human pathology*. 1999;30(3):295-9. PubMed PMID: 10088548.
24. Nemeth JA, Harb JF, Barroso U, Jr., He Z, Grignon DJ, **Cher ML**. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. *Cancer research*. 1999;59(8):1987-93. PubMed PMID: 10213511.
25. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, **Cher ML**. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 1999;5(12):4105-10. PubMed PMID: 10632347.
26. Virgin JB, Hurley PM, Nahhas FA, Bechuk KG, Mohamed AN, Sakr WA, Bright RK, **Cher ML**. Isochromosome 8q formation is associated with 8p loss of heterozygosity in a prostate cancer cell line. *The Prostate*. 1999;41(1):49-57. PubMed PMID: 10440875.
27. Hukku B, Mally M, **Cher ML**, Peehl DM, Kung H, Rhim JS. Stepwise genetic changes associated with progression of nontumorigenic HPV-18 immortalized human prostate cancer-derived cell line to a malignant phenotype. *Cancer genetics and cytogenetics*. 2000;120(2):117-26. PubMed PMID: 10942801.
28. Nemeth JA, Roberts JW, Mullins CM, **Cher ML**. Persistence of human vascular endothelium in experimental human prostate cancer bone tumors. *Clinical & experimental metastasis*. 2000;18(3):231-7. PubMed PMID: 11315096.
29. Toth M, Bernardo MM, Gervasi DC, Soloway PD, Wang Z, Bigg HF, Overall CM, DeClerck YA, Tschesche H, **Cher ML**, Brown S, Mobashery S, Fridman R. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. *The Journal of biological chemistry*. 2000;275(52):41415-23. doi: 10.1074/jbc.M006871200. PubMed PMID: 10998420.
30. Bianco FJ, Jr., Wood DP, Jr., Gomes de Oliveira J, Nemeth JA, Beaman AA, **Cher ML**. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. *The Prostate*. 2001;49(4):235-42. PubMed PMID: 11746269.
31. Dong Z, Nemeth JA, **Cher ML**, Palmer KC, Bright RC, Fridman R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. *International journal of cancer Journal international du cancer*. 2001;93(4):507-15. PubMed PMID: 11477554.
32. Bianco FJ, Jr., Powell IJ, **Cher ML**, Wood DP, Jr. Presence of circulating prostate cancer cells in African American males adversely affects survival. *Urologic oncology*. 2002;7(4):147-52. PubMed PMID: 12474530.
33. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, **Cher ML**. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. *Journal of the National Cancer Institute*. 2002;94(1):17-25. PubMed PMID: 11773278.

34. Powell IJ, Dey J, Dudley A, Pontes JE, **Cher ML**, Sakr W, Grignon DJ, Wood DP. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. *Urology*. 2002;59(6):907-12. PubMed PMID: 12031379.
35. Bianco FJ, Jr., Wood DP, Jr., **Cher ML**, Powell IJ, Souza JW, Pontes JE. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. *Clinical prostate cancer*. 2003;1(4):242-7. PubMed PMID: 15040883.
36. **Cher ML**, Biliran HR, Jr., Bhagat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zacharek M, Sheng S. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(13):7847-52. doi: 10.1073/pnas.1331360100. PubMed PMID: 12788977; PubMed Central PMCID: PMC164676.
37. Mohla S, Weilbacher KN, **Cher ML**, Oyajobi BO, Poznak CV, Clohisy DR. Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions. *Cancer*. 2003;97(3 Suppl):719-25. doi: 10.1002/cncr.11136. PubMed PMID: 12548568.
38. Nemeth JA, **Cher ML**, Zhou Z, Mullins C, Bhagat S, Trikha M. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. *Clinical & experimental metastasis*. 2003;20(5):413-20. PubMed PMID: 14524530.
39. Nie D, Nemeth J, Qiao Y, Zacharek A, Li L, Hanna K, Tang K, Hillman GG, **Cher ML**, Grignon DJ, Honn KV. Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. *Clinical & experimental metastasis*. 2003;20(7):657-63. PubMed PMID: 14669797.
40. Li Y, Che M, Bhagat S, Ellis KL, Kucuk O, Doerge DR, Abrams J, **Cher ML**, Sarkar FH. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. *Neoplasia*. 2004;6(4):354-63. doi: 10.1593/neo.03478. PubMed PMID: 15256057; PubMed Central PMCID: PMC1502110.
41. Rotenberg RG, Rozas NS, Guerri L, **Cher ML**, Gamboni M, Lema N, Bonfil RD. Elevated levels of angiostatin in effusions from patients with malignant disease. *Oncology reports*. 2004;11(2):523-8. PubMed PMID: 14719094.
42. Scharovsky OG, Binda MM, Rozados VR, Bhagat S, **Cher ML**, Bonfil RD. Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance. *Clinical & experimental metastasis*. 2004;21(2):177-83. PubMed PMID: 15168735.
43. Ustach CV, Taube ME, Hurst NJ, Jr., Bhagat S, Bonfil RD, **Cher ML**, Schuger L, Kim HR. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. *Cancer research*. 2004;64(5):1722-9. PubMed PMID: 14996732; PubMed Central PMCID: PMC4171134.
44. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R, **Cher ML**. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. *The American journal of pathology*. 2005;166(4):1173-86. doi: 10.1016/S0002-9440(10)62337-1. PubMed PMID: 15793297; PubMed Central PMCID: PMC1602391.

45. Fromont G, Valeri A, **Cher M**, Pontes JE, Vallancien G, Validire P, Latil A, Cussenot O. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer. *The Prostate*. 2005;65(4):341-6. doi: 10.1002/pros.20304. PubMed PMID: 16015610.
46. Podgorski I, Linebaugh BE, Sameni M, Jedeszko C, Bhagat S, **Cher ML**, Sloane BF. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. *Neoplasia*. 2005;7(3):207-23. doi: 10.1593/neo.04349. PubMed PMID: 15799821; PubMed Central PMCID: PMC1501133.
47. Sloane BF, Yan S, Podgorski I, Linebaugh BE, **Cher ML**, Mai J, Cavallo-Medved D, Sameni M, Dosesco J, Moin K. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. *Seminars in cancer biology*. 2005;15(2):149-57. doi: 10.1016/j.semcancer.2004.08.001. PubMed PMID: 15652460.
48. Valeri A, Fromont G, Sakr W, Azzouzi R, Dey J, Chantrel-Groussard K, Latil A, Berthon P, Cussenot O, Pontes JE, **Cher ML**. High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy. *Urologic oncology*. 2005;23(2):87-92. doi: 10.1016/j.urolonc.2004.08.015. PubMed PMID: 15869992.
49. Bonfil RD, Sabbota A, Nabha S, Bernardo MM, Dong Z, Meng H, Yamamoto H, Chinni SR, Lim IT, Chang M, Filetti LC, Mobashery S, **Cher ML**, Fridman R. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. *International journal of cancer Journal international du cancer*. 2006;118(11):2721-6. doi: 10.1002/ijc.21645. PubMed PMID: 16381009.
50. **Cher ML**, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA, Chung LW. Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. *The American journal of pathology*. 2006;168(5):1405-12. doi: 10.2353/ajpath.2006.050874. PubMed PMID: 16651608; PubMed Central PMCID: PMC1606588.
51. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, **Cher ML**. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. *The Prostate*. 2006;66(1):32-48. doi: 10.1002/pros.20318. PubMed PMID: 16114056.
52. Deng X, Bhagat S, Dong Z, Mullins C, Chinni SR, **Cher M**. Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel. *European journal of cancer*. 2006;42(18):3267-73. doi: 10.1016/j.ejca.2006.07.003. PubMed PMID: 16950615.
53. Li Y, Kucuk O, Hussain M, Abrams J, **Cher ML**, Sarkar FH. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. *Cancer research*. 2006;66(9):4816-25. doi: 10.1158/0008-5472.CAN-05-3752. PubMed PMID: 16651437.
54. Nabha SM, Bonfil RD, Yamamoto HA, Belizi A, Wiesner C, Dong Z, **Cher ML**. Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis. *Clinical & experimental metastasis*. 2006;23(7-8):335-44. doi: 10.1007/s10585-006-9042-x. PubMed PMID: 17136575.

55. Yin S, Lockett J, Meng Y, Biliran H, Jr., Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, **Cher ML**, Sheng S. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. *Cancer research*. 2006;66(8):4173-81. doi: 10.1158/0008-5472.CAN-05-3514. PubMed PMID: 16618739.
56. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, **Cher M**, Sarkar FH. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. *Cancer research*. 2007;67(8):3818-26. doi: 10.1158/0008-5472.CAN-06-3879. PubMed PMID: 17440096.
57. Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, Nabha S, Yamamoto H, Chinni SR, Zhao H, Mobashery S, Vessella RL, Fridman R, **Cher ML**. Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. *The American journal of pathology*. 2007;170(6):2100-11. doi: 10.2353/ajpath.2007.060720. PubMed PMID: 17525276; PubMed Central PMCID: PMC1899437.
58. Vaishampayan U, Hussain M, Banerjee M, Seren S, Sarkar FH, Fontana J, Forman JD, **Cher ML**, Powell I, Pontes JE, Kucuk O. Lycopene and soy isoflavones in the treatment of prostate cancer. *Nutrition and cancer*. 2007;59(1):1-7. doi: 10.1080/01635580701413934. PubMed PMID: 17927495.
59. Wiesner C, Bonfil RD, Dong Z, Yamamoto H, Nabha SM, Meng H, Saliganan A, Sabbota A, **Cher ML**. Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction. *Urology*. 2007;69(4):795-9. doi: 10.1016/j.urology.2007.01.093. PubMed PMID: 17445684.
60. Yamamoto H, Bonfil RD, Wiesner C, Nabha S, Dong Z, Meng H, Saliganan A, Sabbota A, Chinni SR, **Cher ML**. Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging. *The Prostate*. 2007;67(1):107-14. doi: 10.1002/pros.20506. PubMed PMID: 17075820.
61. Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, **Cher ML**. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. *Molecular cancer research : MCR*. 2008;6(3):446-57. doi: 10.1158/1541-7786.MCR-07-0117. PubMed PMID: 18337451; PubMed Central PMCID: PMC3842603.
62. Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, **Cher ML**. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. *Neoplasia*. 2008;10(5):439-49. PubMed PMID: 18472961; PubMed Central PMCID: PMC2373914.
63. Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, Saliganan A, Kim HR, **Cher ML**, Sarkar FH. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. *Stem cells*. 2008;26(6):1425-35. doi: 10.1634/stemcells.2007-1076. PubMed PMID: 18403754; PubMed Central PMCID: PMC3766351.
64. Nabha SM, dos Santos EB, Yamamoto HA, Belizi A, Dong Z, Meng H, Saliganan A, Sabbota A, Bonfil RD, **Cher ML**. Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. *International journal of cancer Journal international du cancer*. 2008;122(11):2482-90. doi: 10.1002/ijc.23431. PubMed PMID: 18324629; PubMed Central PMCID: PMC3842601.

65. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thuroff JW, Vessella RL, **Cher ML**, Bonfil RD. C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. *Neoplasia*. 2008;10(9):996-1003. PubMed PMID: 18714401; PubMed Central PMCID: PMC2517645.
66. Vaishampayan UN, Marur S, Heilbrun LK, **Cher ML**, Dickow B, Smith DW, Al Hasan SA, Eliason J. Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. *The Journal of urology*. 2009;182(1):317-23. doi: 10.1016/j.juro.2009.02.105. PubMed PMID: 19447430; PubMed Central PMCID: PMC3869185.
67. Ahmad IU, Forman JD, Sarkar FH, Hillman GG, Heath E, Vaishampayan U, **Cher ML**, Andic F, Rossi PJ, Kucuk O. Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. *Nutrition and cancer*. 2010;62(7):996-1000. doi: 10.1080/01635581.2010.509839. PubMed PMID: 20924975; PubMed Central PMCID: PMC3856358.
68. Cai J, Kandagatla P, Singareddy R, Kropinski A, Sheng S, **Cher ML**, Chinni SR. Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells. *Translational oncology*. 2010;3(3):195-203. PubMed PMID: 20563261; PubMed Central PMCID: PMC2887649.
69. Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD, **Cher ML**. Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. *Cancer research*. 2010;70(13):5558-66. doi: 10.1158/0008-5472.CAN-09-4416. PubMed PMID: 20551048; PubMed Central PMCID: PMC2896434.
70. Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, Dean I, Krass D, Moin K, Bonfil RD, **Cher M**, Sakr W, Sheng S. Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. *Genes & cancer*. 2011;2(11):1009-22. doi: 10.1177/1947601912440170. PubMed PMID: 22737267; PubMed Central PMCID: PMC3379563.
71. Dhar N, Ward JF, **Cher ML**, Jones JS. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. *BJU international*. 2011;108(4):508-12. doi: 10.1111/j.1464-410X.2011.10238.x. PubMed PMID: 21722288.
72. Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, **Cher ML**, Chen YQ, Kim HR. PTEN regulates PDGF ligand switch for beta-PDGFR signaling in prostate cancer. *The American journal of pathology*. 2012;180(3):1017-27. doi: 10.1016/j.ajpath.2011.11.021. PubMed PMID: 22209699; PubMed Central PMCID: PMC3349886.
73. Huang W, Fridman Y, Bonfil RD, Ustach CV, Conley-LaComb MK, Wiesner C, Saliganan A, **Cher ML**, Kim HR. A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. *Oncogene*. 2012;31(42):4527-35. doi: 10.1038/onc.2011.573. PubMed PMID: 22158043; PubMed Central PMCID: PMC3482867.
74. Kong D, Heath E, Chen W, **Cher M**, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. *American journal of translational research*. 2012;4(1):14-23. PubMed PMID: 22347519; PubMed Central PMCID: PMC3275434.

75. Kong D, Heath E, Chen W, **Cher ML**, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. *PLoS one*. 2012;7(3):e33729. doi: 10.1371/journal.pone.0033729. PubMed PMID: 22442719; PubMed Central PMCID: PMC3307758.
76. Najy AJ, Jung YS, Won JJ, Conley-LaComb MK, Saliganan A, Kim CJ, Heath E, **Cher ML**, Bonfil RD, Kim HR. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. *The Prostate*. 2012;72(12):1328-38. doi: 10.1002/pros.22481. PubMed PMID: 22213159; PubMed Central PMCID: PMC3369116.
77. Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, **Cher ML**, Chinni SR. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. *Molecular cancer*. 2013;12(1):85. doi: 10.1186/1476-4598-12-85. PubMed PMID: 23902739; PubMed Central PMCID: PMC3751767.
78. Kong D, Heath E, Chen W, **Cher M**, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr W, Menon M, Sarkar F. Erratum: Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. *American journal of translational research*. 2013;6(1):102-3. PubMed PMID: 24349627; PubMed Central PMCID: PMC3853430.
79. Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W, **Cher ML**, Chinni SR. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. *Molecular cancer research : MCR*. 2013;11(11):1349-61. doi: 10.1158/1541-7786.MCR-12-0705. PubMed PMID: 23918819; PubMed Central PMCID: PMC3901058.
80. Veenstra JJ, Gibson HM, Littrup PJ, Reyes JD, **Cher ML**, Takashima A, Wei WZ. Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. *Cancer research*. 2014;74(19):5409-20. doi: 10.1158/0008-5472.CAN-14-0501. PubMed PMID: 25092895; PubMed Central PMCID: PMC4185007.
81. Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, **Cher ML**, Heath E, Fridman R, Kim HR, Bonfil RD. Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth. *International journal of cancer Journal international du cancer*. 2015;136(1):11-20. doi: 10.1002/ijc.28948. PubMed PMID: 24798488; PubMed Central PMCID: PMC4199873.
82. Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, **Cher ML**, Chinni SR. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2015;21(11):2569-79. doi: 10.1158/1078-0432.CCR-14-2352. PubMed PMID: 25754347.
83. Ross I, Womble P, Ye J, Linsell S, Montie JE, Miller DC, **Cher ML**. MUSIC: patterns of care in the radiographic staging of men with newly diagnosed low risk prostate cancer. *The Journal of urology*. 2015;193(4):1159-62. doi: 10.1016/j.juro.2014.10.102. PubMed PMID: 25444985.
84. Tay KJ, Polascik TJ, Elshafei A, **Cher ML**, Given RW, Mouraviev V, Ross AE, Jones JS. [Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and](#)

- [Functional Outcomes from the COLD Registry](#). J Endourol. 2016 Jan;30(1):43-8. doi: 10.1089/end.2015.0403. Epub 2015 Oct 20. PMID: 26414656
85. Morgan TM, Hawken SR, Ghani KR, Miller DC, Feng FY, Linsell SM, Salisz JA, Gao Y, Montie JE, **Cher ML**. [Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy](#). Prostate Cancer Prostatic Dis. 2016 Jun;19(2):216-21. doi: 10.1038/pcan.2016.9. Epub 2016 Mar 8. PMID: 26951715.
86. Cho WJ, Oliveira DS, Najy AJ, Mainetti LE, Aoun HD, **Cher ML**, Heath E, Kim HR, Bonfil RD. [Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients](#). J Transl Med. 2016 Mar 15;14:72. doi: 10.1186/s12967-016-0829-5. PMID: 26975354.
87. **Cher ML**, Dhir A, Auffenberg GB, Linsell S, Gao Y, Rosenberg B, Jafri SM, Klotz L, Miller DC, Ghani KR, Bernstein SJ, Montie JE, Lane BR; Michigan Urological Surgery Improvement Collaborative. [Appropriateness Criteria for Active Surveillance of Prostate Cancer](#). J Urol. 2017 Jan;197(1):67-74. doi: 10.1016/j.juro.2016.07.005. PMID: 27422298
88. Conley-LaComb MK, Semaan L, Singareddy R, Li Y, Heath EI, Kim S, **Cher ML**, Chinni SR. [Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis](#). Mol Cancer. 2016 Nov 3;15(1):68.
89. Evans R, Loeb A, Kaye K, **Cher ML**, Martin ET. Infection-Related Hospital Admissions Following Prostate Biopsy in United States Men. In press, Open Forum Infectious Disease, 2016.

Reviews

1. **Cher ML**, Carroll PR. Screening for prostate cancer. The Western journal of medicine. 1994;160(3):250. PubMed PMID: 7514824; PubMed Central PMCID: PMC1022392.
2. **Cher ML**, Carroll PR. Screening for prostate cancer. The Western journal of medicine. 1995;162(3):235-42. PubMed PMID: 7536993; PubMed Central PMCID: PMC1022708.
3. Honn KV, Aref A, Chen YQ, **Cher ML**, Crissman JD, Forman JD, Gao X, Grignon D, Hussain M, Porter AT, Pontes EJ, Powell II, Redman B, Sakr W, Severson R, Tang DG, Wood DP, Jr. Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects). Pathology oncology research : POR. 1996;2(3):191-211. PubMed PMID: 11173606.
4. Honn KV, Aref A, Chen YQ, **Cher ML**, Crissman JD, Forman JD, Gao X, Grignon D, Hussain M, Porter AT, Pontes JE, Powell I, Redman B, Sakr W, Severson R, Tang DG, Wood DP. Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations. Pathology oncology research : POR. 1996;2(1-2):98-109. doi: 10.1007/BF02893960. PubMed PMID: 18443924.
5. Honn KV, Aref A, Chen YQ, **Cher ML**, Crissman JD, Forman JD, Gao X, Grignon D, Hussain M, Porter AT, Pontes JE, Powell II, Redman B, Sakr W, Severson R, Tang DG, Wood DP, Jr. Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment. Pathology oncology research : POR. 1996;2(4):276-92. PubMed PMID: 11173616.

6. Hillman GG, Triest JA, **Cher ML**, Kocheril SV, Talati BR. Prospects of immunotherapy for the treatment of prostate carcinoma--a review. *Cancer detection and prevention*. 1999;23(4):333-42. PubMed PMID: 10403905.
7. **Cher ML**. Mechanisms governing bone metastasis in prostate cancer. *Current opinion in urology*. 2001;11(5):483-8. PubMed PMID: 11493769.
8. Narain V, **Cher ML**, Wood DP, Jr. Prostate cancer diagnosis, staging and survival. *Cancer metastasis reviews*. 2002;21(1):17-27. PubMed PMID: 12400994.
9. Bonfil RD, Osenkowski P, Fridman R, **Cher ML**. Matrix metalloproteinases and bone metastasis. *Cancer treatment and research*. 2004;118:173-95. PubMed PMID: 15043193.
10. Bonfil RD, Chinni S, Fridman R, Kim HR, **Cher ML**. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. *Urologic oncology*. 2007;25(5):407-11. doi: 10.1016/j.urolonc.2007.05.008. PubMed PMID: 17826661.
11. Bonfil RD, Fridman R, Mobashery S, **Cher ML**. Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis? *Current oncology*. 2008;15(4):188-92. PubMed PMID: 18769612; PubMed Central PMCID: PMC2528310.
12. Bonfil RD, **Cher ML**. The role of proteolytic enzymes in metastatic bone disease. *IBMS BoneKey*. 2011 January;8(1):16-36
13. Zhe X, **Cher ML**, Bonfil RD. Circulating tumor cells: finding the needle in the haystack. *American journal of cancer research*. 2011;1(6):740-51. PubMed PMID: 22016824; PubMed Central PMCID: PMC3195935.

BOOKS AND CHAPTERS

1. **Cher ML**, Roehrborn CR: Incorporation of intestinal segments into the urinary tract. In: *Societe Internationale d'Urologie Reports, Continent Urinary Diversion*. Eds: Hohenfellner R, Wammack R, 1992.
2. Allen TD, **Cher ML**, Ewalt DH: Enterocystoplasty without bladder neck surgery for patients with neurogenic bladders resulting from myelodysplasia. In: *Societe Internationale d'Urologie Reports, Pediatric Urology*, 1994.
3. **Cher ML**, Carroll PR: Surgical anatomy of the bladder. In: *Principles and Practice of Genitourinary Oncology*. Eds: Raghavan D, Scher HI, Leibel SA and Lange PH, 1997.
4. **Cher ML**, Carroll PR, Small EJ, Shinohara K: Neoadjuvant androgen deprivation before radical prostatectomy: current status and trial design. In: *Prostate Cancer*. Eds: Dawson N, Vogelzang N, p 175-183, 1994.
5. **Cher ML**, Carroll PR: Continent Urinary Diversion. In: *Reconstructive Urology*. Eds: McAninch J, 1996.
6. Aboseif SR, **Cher ML**, Carroll PR: Neobladder Development. In: *New Techniques in Reconstructive Urology*. Ed: McAninch JW, 1995.

7. **Cher ML**, Harb JF, Nemeth JA: Animal model systems for the study of prostate cancer. In: Advances in Oncobiology, Vol. 3: The Oncobiology of the Prostate. Ed: Wood DP and Honn KV, 1999.
8. Nemeth JA, **Cher ML**: Biology of prostate cancer bone marrow metastasis. In: Advances in Oncobiology, Vol. 3: The Oncobiology of the Prostate. Ed: Wood DP and Honn KV, 1999.
9. **Cher ML**, Nemeth JA: The Bone Microenvironment. In: American Cancer Society Atlas of Clinical Oncology: Prostate Cancer. Ed: Carroll PR, Grossfeld GD, 2002.
10. Bonfil RD, Osenkowki P, Fridman R, **Cher ML**: Matrix Metalloproteinases And Bone Metastasis. In Keller ET and Chung LW (eds), The Biology of Skeletal Metastases, Kluwer Academic Publishers, Boston, MA. 2004. p 173-96.

PATENTS

- 9/02 United States Patents 6,451,529: Genetic Alterations Associated with Prostate Cancer.
- 7/99 United States Patents 5,925,519: Genetic Alterations Associated with Prostate Cancer.

PRESENTATIONS

National/International:

- 9/7/96 Research meeting, Association for the Cure of Cancer of the Prostate (CaPCURE), Lake Tahoe, CA: "Genomic alterations and cellular proliferation in prostate cancer in African Americans"
- 9/13/96 Invited Speaker, University of Chicago Prostate Cancer Research Seminar, Chicago, IL: "Chromosomal alterations in human metastatic prostate cancer"
- 1/27/96 Invited Speaker, National Conference on Hereditary Prostate Cancer in African Americans, Bethesda, MD: "Chromosomal alterations in prostate cancer in African Americans"
- 3/30/98 Invited Speaker, Windsor Urology Group, Windsor, Canada: "Translational research in bladder cancer"
- 4/20/98 Invited Speaker, National Review Course of Urology, Chicago, IL: "Uroepithelial tumors of the bladder and upper urinary tract." Also provided lecture material which was published in course syllabus; presentation video taped and sold separately as instructional material
- 8/14/98 Invited Speaker, Instituto Oncologico Henry Moore, Buenos Aires, Argentina: "Gold Standard en Cancer de Prostata Estadios C y D"

- 3/22/99 Invited Speaker, Protease Consortium Meeting, Nashville, TN: "A New Experimental Model of Prostate Cancer Bone Metastasis"
- 10/7/99 Podium Presentation, The 3rd World Congress on Urological Research, Paris, France: "Matrix metalloproteinase expression in the SCID-human model of human prostate cancer metastasis to human bone." Received 1st prize for best prostate cancer research presentation.
- 10/27/99 Visiting Professor, University of British Columbia and Vancouver General Hospital, Vancouver, CA: "Prostate cancer bone marrow micrometastases," and "SCID-human model of human prostate cancer metastasis to human bone."
- 1/26/00 Visiting Professor, The University of Wisconsin Comprehensive Cancer Center Grand Rounds, Madison, WI: "Matrix metalloproteinase expression in the SCID-human model of human prostate cancer metastasis to human bone."
- 7/27/00 Invited Speaker, Prostate Program and Protease Program of the Comprehensive Cancer Center, The University of California, San Francisco School of Medicine: "Prostate Cancer Bone Metastasis"
- 9/15/00 Visiting Professor, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Rockville, MD: (1) "Prostate cancer metastasis: experimental approach," and (2) "Clinical evaluation of prostate cancer metastasis"
- 9/21/00 Invited Speaker, Association for the Cure of Cancer of the Prostate (CaPCURE) 7th Annual Scientific Meeting, podium presentation, Lake Tahoe, CA: "Genetically modified bone stroma in the SCID-human model: a novel experimental approach for therapy of prostate cancer bone metastasis"
- 5/15/01 Visiting Professor, The University of Texas M.D. Anderson Department of Cancer Biology, Houston, TX: "Prostate cancer metastasis: experimental approach"
- 6/2/01 Invited Speaker, The Society of Urologic Oncology, Annual Meeting, Anaheim, CA: "Novel Models of Prostate Cancer Bone Metastasis"
- 6/19/01 Visiting Professor, The Ohio State University Urologic Oncology Program, Columbus, OH: "Matrix Metalloproteinases and the SCID-Human Model of Prostate Cancer Bone Metastasis"
- 7/23/01 Visiting Professor, The University of Minnesota Cancer Center, Minneapolis, MN: "Matrix Metalloproteinases and the SCID-Human Model of Prostate Cancer Bone Metastasis"
- 12/01 Invited Speaker, American Association for Cancer Research Special Conference on Prostate Cancer, Naples, FL: "SCID-Human Model of Prostate Cancer Bone Metastasis: Study of Bone-Tumor Interactions"
- 4/02 Invited Speaker, Third North American Symposium on Skeletal Complications of Malignancy, sponsored by NCI and Paget's Foundation, Bethesda, MD.
- 9/02 Invited Speaker, IXth International Congress of the Metastasis Research Society,

- Chicago, IL: "Experimental Approach to Prostate Cancer Bone Metastasis"
- 11/02 Visiting Professor, Cleveland Clinic Foundation Lerner Research Institute, Cleveland, OH: "Experimental Approach to Prostate Cancer Bone Metastasis"
- 11/02 Invited Speaker, National Cancer Institute Proteases and Cancer Workshop, Bethesda, MD: "Matrix metalloproteinases and Bone Metastasis"
- 12/02 Invited Speaker, Society of Urologic Oncology/National Cancer Institute, Bethesda, MD: "Protease Activity in Prostate Cancer Bone Metastasis"
- 2/03 Invited Speaker, University of Colorado Department of Urology, Denver, CO: "Prostate Cancer Bone Metastasis"
- 7/03 Visiting Professor, Louisiana State University Scott Cancer Center, New Orleans, LA: "Experimental Approach to Prostate Cancer Bone Metastasis"
- 8/03 Invited Speaker, American Urological Association Summer Research Conference, Houston, TX: "Prostate Growth in Benign and Malignant Disease"
- 9/03 Invited Speaker, Washington University, Siteman Comprehensive Cancer Center, St. Louis, MO: "Protease Activity and Prostate Cancer Bone Metastasis"
- 10/03 Invited Speaker, Prostate Cancer 2003, New Perspectives, Baltimore, MD: "Protease Activity and Bone Metastasis"
- 12/03 Invited Speaker: Society of Urologic Oncology and National Cancer Institute 2003, Bethesda, MD: "Regulation of Gene Expression and Inhibition of Metastasis by Genistein"
- 12/03 Invited Speaker: IVth International Conference on Cancer Induced Bone Disease, San Antonio, TX: "Regulation of Gene Expression and Inhibition of Metastasis by Genistein"
- 1/04 Invited Speaker, Urology Department, University of Texas Southwestern School of Medicine: "Protease Activity and Prostate Cancer Bone Metastasis"
- 1/04 Invited Speaker, Physiology and Biochemistry Department, University of Iowa School of Medicine, Iowa City, IA: "Protease Activity and Prostate Cancer Bone Metastasis"
- 11/04 Invited Speaker, University of California Davis School of Medicine, Cancer Center Grand Rounds, Sacramento, CA: "Prostate Cancer Bone Metastasis"
- 5/06 Invited Speaker, Society of Urologic Oncology National Meeting, Atlanta, GA: Translational Aspects of Prostate Cancer Bone Biology: Growth Factors, Chemokines, and Proteases.
- 6/06 Invited Speaker: Great Lakes Family Medicine Conference, Birmingham, MI: (1) Prostate Cancer, Prevention, and BPH; (2) Erectile Dysfunction for the Family Physician.

- 6/07 Invited Speaker: Great Lakes Family Medicine Conference, Birmingham, MI: (1) Prostate Cancer, Prevention, and BPH; (2) Erectile Dysfunction for the Family Physician.
- 8/07 Invited Speaker, 7th Annual Update in Internal Medicine, Selected Topics and Controversies. (1) Urinary Incontinence; (2) Erectile Dysfunction. Bay Harbor, MI.
- 9/07 Invited Speaker, United States Department of Defense Prostate Cancer Research Program IMPaCT Meeting, Atlanta, GA. MT1-MMP: A Pivotal Role in Prostate Cancer Bone Metastasis.
- 4/09 Invited Speaker, Saudi Cancer Foundation 2009 Genitourinary Cancer Conference, Al Khobar, Saudi Arabia. Multiple lectures in urologic oncology.
- 6/09 Invited Speaker, Washington University School of Medicine Department of Urology Course: Highlights of the AUA – Prostate Cancer.
- 5/12 Invited Speaker, Society of Urologic Oncology National Meeting, Atlanta, GA: New therapeutic targets in prostate cancer bone metastasis.
- 7/12 Invited Speaker, Friends of Israel Urological Symposium, Tel Aviv, Israel: (1) Continuous vs. Intermittent Androgen Deprivation; (2) Clinical outcome of positive margins; (3) New therapeutic targets in advanced prostate cancer.
- 9/12 Visiting Professor, Washington University School of Medicine, Department of Urology. Three lectures and journal club.
- 3/13 Visiting Professor, New York University College of Dentistry: Bone metastasis research.

Local/Regional (Selected):

- 10/4/96 Invited Speaker, Great Lakes International Image and Flow Cytometry meeting, Detroit, MI: “Molecular Cytogenetic Evaluation of Human Metastatic Prostate Cancer”
- 11/15/96 Invited Speaker, Urology Nursing '96, Romulus, MI: “Current Concepts in Management of Localized Prostate Cancer”
- 5/13/97 Invited Speaker, University of Michigan Urologic Oncology Conference: “Molecular Cytogenetics of Prostate Cancer”
- 10/17/97 Faculty Speaker, Wayne State University Bladder Cancer Course: “Chromosomal Alterations in Bladder Cancer”
- 1/14/98 Invited Speaker, Michigan Urological Society: “Predicting the bone scan result after failed primary therapy for prostate cancer”
- 5/8/98 Faculty Speaker, Pierce Memorial Lecture, Wayne State University: “Biological aspects of prostate cancer bone marrow metastasis”

- 12/14/98 Invited Speaker, Breast Cancer Biology Group, Wayne State University: "SCID-human model of prostate cancer bone metastasis"
- 4/9/99 Faculty Speaker, Pierce Memorial Lecture, Wayne State University: "A New Experimental Model of Prostate Cancer Bone Metastasis"
- 5/13/99 Invited Speaker, Internal Medicine Grand Rounds, Grace Hospital, Detroit, MI: "Biological Aspects of Prostate Cancer Bone Metastasis"
- 5/20/99 Invited Speaker, Internal Medicine Grand Rounds, Sinai Hospital, Detroit, MI: "Biological Aspects of Prostate Cancer Bone Metastasis"
- 8/4/99 Invited Speaker, General Staff Grand Rounds, Oakwood Hospital Heritage Center, Taylor, MI. "Carcinoma of the Prostate, Present Day Controversies & Management"
- 10/11/99 Invited Speaker, Michigan Prostate Research Colloquium: "SCID-human model of human prostate cancer metastasis to human bone"
- 11/11/99 Invited Speaker, The Barbara Ann Karmanos Cancer Institute Grand Rounds: "Matrix metalloproteinase expression in the SCID-human model of human prostate cancer metastasis to human bone"
- 12/13/99 Invited Speaker, The University of Michigan SPORE in Prostate Cancer: "Matrix metalloproteinase expression in the SCID-human model of human prostate cancer metastasis to human bone"
- 3/8/00 Invited Speaker, The Barbara Ann Karmanos Cancer Institute Developmental Therapeutics Program: "New Directions in the SCID-human model of human prostate cancer metastasis to human bone"
- 5/16/00 Invited Speaker, The John D. Dingell Veteran's Affairs Medical Center Research Service: "Prostate Cancer Bone Metastasis: Experimental Approach"
- 7/19/00 Invited Speaker, Division of Endocrinology Grand Rounds, Department of Internal Medicine, Wayne State University School of Medicine: "Prostate Cancer Bone Metastasis: Experimental Approach"
- 10/19/00 Invited Speaker, Crittenton Hospital Prostate Cancer Support Group: "Prostate Cancer Research"
- 10/19/00 Invited Speaker, Norman N. Krieger Lecture in Geriatric Medicine, Sponsored by Huron Valley Sinai Hospital: "Prostate Cancer in the Geriatric Population"
- 2/19/03 Invited Speaker, WSU Dept of Pathology Lecture Series: "Prostate Cancer Bone Metastasis"
- 3/15/03 Invited Speaker, The 5th Great Lakes Urology Seminar, Troy, MI: "Modern Applications of Prostate Specific Antigen Variants and PSA Protease Biology"
- 12/03 Invited Speaker, The Ehinger Endowed Fund in Radiation Oncology Education, Spectrum Health Cancer Center, Grand Rapids, MI. "Multidisciplinary Treatment

for Locally Advanced Prostate Cancer”

- 10/04 Invited Speaker, Pierce Memorial Urology Conference, Dearborn, MI: “Prostate Cryotherapy”
- 2/05 Invited Speaker, Urology Update Nursing Conference, The Barbara Ann Karmanos Cancer Institute: “Prostate Cryoablation”
- 7/05 Invited Speaker, 5th Annual Update in Internal Medicine, WSU School of Medicine, Selected Topics and Controversies, Petoskey, MI: Updates in Benign and Malignant Prostate Disease.
- 3/06 Invited Speaker, Great Lakes Urology Seminar, Novi, MI: “Debate on Timing of Androgen Deprivation Therapy in Patients with a Rising PSA after Primary Therapy”
- 11/06 Invited Speaker, Norman N. Krieger Lecture in Geriatric Medicine, Sponsored by Huron Valley Sinai Hospital: “Prostate Cancer and BPH”
- 1/07 Conference Organizer and Speaker: Michigan Urological Society Scientific Meeting. “Update on Cryotherapy as Salvage Treatment for Locally Recurrent Prostate Cancer.”
- 4/07 Invited Keynote Speaker, Oakwood Hospital and Medical Center Resident Research Day: Prostate Cancer Bone Metastasis and Cryoimmunotherapy.
- 3/08 Conference Organizer and Speaker: Michigan Urological Society Great Lakes Urology Annual Review Meeting. Recruited speakers from U of M, Beaumont, and Henry Ford.
- 3/12 Invited Speaker, University of Michigan Urology Grand Rounds, Ann Arbor, MI. “New insights into Prostate Cancer Bone Metastasis.”
- 10/12 Invited Speaker, St. Nicholas Greek Orthodox Church, Troy, MI: Cancer Care at the Karmanos Cancer Institute.
- 1/13 Invited Speaker, Wayne State University Department of Medicine Grand Rounds: Update on Prostate Cancer Treatment